Fibromyalgia Reason 5 O O
symptoms Reason 5 O O
were Reason 5 O O
reduced Reason 5 O O
at Reason 5 O O
both Reason 5 O O
4 Reason 5 O O
and Reason 5 O O
12 Reason 5 O O
weeks Reason 5 O O
in Reason 5 O O
patients Reason 5 O O
receiving Reason 5 O O
tocilizumab Reason 5 O O
treatment. Reason 5 O O
Patients Reason 5 O O
with Reason 5 O O
[fibromyalgia](https://www.hcplive.com/clinical/fibromyalgia) Reason 5 O O
may Reason 5 O O
benefit Reason 5 O O
from Reason 5 O O
subcutaneous Reason 5 O O
tocilizumab Reason 5 O O
therapy, Reason 5 O O
although Reason 5 O O
a Reason 5 O O
randomized Reason 5 O O
controlled Reason 5 O O
trial Reason 5 O O
is Reason 5 O O
needed Reason 5 O O
to Reason 5 O O
confirm Reason 5 O O
efficacy, Reason 5 O O
according Reason 5 O O
to Reason 5 O O
a Reason 5 O O
study Reason 5 O O
published Reason 5 O O
in Reason 5 O O
Biomedicines.1 Reason 5 O O
The O O O O
treatment O O O O
efficacy O O O O
of O O O O
fibromyalgia O O O O
is O O O O
limited, O O O O
and O O O O
its O O O O
pathogenesis O O O O
remains O O O O
elusive. O O O O
However, O O O O
researchers Reason 4 O O
believe Reason 4 O O
it Reason 4 O O
involves Reason 4 O O
immune Reason 4 O O
dysregulation Reason 4 O O
including Reason 4 O O
pro-inflammatory Reason 4 O O
cytokines, Reason 4 O O
such Reason 4 O O
as Reason 4 O O
interleukin-6 Reason 4 O O
(IL-6). Reason 4 O O
Patients Reason 4 O O
with Reason 4 O O
other Reason 4 O O
rheumatic Reason 4 O O
diseases Reason 4 O O
are Reason 4 O O
also Reason 4 O O
more Reason 4 O O
likely Reason 4 O O
to Reason 4 O O
have Reason 4 O O
a Reason 4 O O
concomitant Reason 4 O O
fibromyalgia Reason 4 O O
diagnosis. Reason 4 O O
Considering Reason 4 O O
these Reason 4 O O
factors, Reason 4 O O
it Reason 4 O O
is Reason 4 O O
likely Reason 4 O O
that Reason 4 O O
the Reason 4 O O
immune Reason 4 O O
system Reason 4 O O
plays Reason 4 O O
an Reason 4 O O
important Reason 4 O O
role Reason 4 O O
in Reason 4 O O
the Reason 4 O O
fibromyalgia-related Reason 4 O O
symptoms Reason 4 O O
of Reason 4 O O
this Reason 4 O O
patient Reason 4 O O
population.2 Reason 4 O O
"To O O O O
date, O O O O
the O O O O
benefits O O O O
of O O O O
fibromyalgia O O O O
treatments O O O O
are O O O O
modest, O O O O
often O O O O
with O O O O
questionable O O O O
clinical O O O O
relevance," O O O O
wrote O O O O
a O O O O
group O O O O
of O O O O
Taiwanese O O O O
investigators. O O O O
"Tocilizumab, Reason 5 O O
a Reason 5 O O
humanized Reason 5 O O
monoclonal Reason 5 O O
antibody Reason 5 O O
against Reason 5 O O
IL-6 Reason 5 O O
receptor, Reason 5 O O
has Reason 5 O O
been Reason 5 O O
shown Reason 5 O O
to Reason 5 O O
be Reason 5 O O
effective Reason 5 O O
against Reason 5 O O
a Reason 5 O O
variety Reason 5 O O
of Reason 5 O O
inflammatory Reason 5 O O
diseases, Reason 5 O O
including Reason 5 O O
rheumatoid Reason 5 O O
arthritis, Reason 5 O O
juvenile Reason 5 O O
idiopathic Reason 5 O O
arthritis, Reason 5 O O
adult-onset Reason 5 O O
Still's Reason 5 O O
disease, Reason 5 O O
giant Reason 5 O O
cell Reason 5 O O
and Reason 5 O O
Takayasu Reason 5 O O
arteritis. Reason 5 O O
Nevertheless, Reason 5 O O
clinical Reason 5 O O
studies Reason 5 O O
on Reason 5 O O
IL-6 Reason 5 O O
inhibition Reason 5 O O
in Reason 5 O O
fibromyalgia Reason 5 O O
patients Reason 5 O O
are Reason 5 O O
basically Reason 5 O O
unavailable." Reason 5 O O
Investigators O O O O
reported O O O O
a O O O O
case O O O O
series O O O O
of O O O O
patients O O O O
with O O O O
fibromyalgia O O O O
receiving O O O O
tocilizumab O O O O
treatment. O O O O
Symptoms O O O O
were O O O O
assessed O O O O
using O O O O
the O O O O
revised O O O O
Fibromyalgia O O O O
Impact O O O O
Questionnaire O O O O
(FIQ), O O O O
which O O O O
evaluated O O O O
pain O O O O
levels, O O O O
and O O O O
the O O O O
2016 O O O O
criteria O O O O
of O O O O
the O O O O
American O O O O
College O O O O
of O O O O
Rheumatology O O O O
(ACR). O O O O
Symptoms O O O O
were O O O O
compared O O O O
using O O O O
the O O O O
Wilcoxon O O O O
signed-rank O O O O
test O O O O
and O O O O
neutrophiles O O O O
from O O O O
patients O O O O
with O O O O
fibromyalgia O O O O
and O O O O
matched O O O O
controls O O O O
were O O O O
isolated O O O O
for O O O O
transcriptome O O O O
analysis. O O O O
Each O O O O
patient O O O O
underwent O O O O
a O O O O
40-joint O O O O
sonography O O O O
at O O O O
baseline, O O O O
including O O O O
the O O O O
elbows, O O O O
wrists, O O O O
knees, O O O O
ankles, O O O O
metacarpophalangeal O O O O
joints, O O O O
and O O O O
thumb O O O O
interphalangeal O O O O
joints. O O O O
The Reason 5 O O
FIQ Reason 5 O O
and Reason 5 O O
general Reason 5 O O
fibromyalgia Reason 5 O O
symptoms Reason 5 O O
improved Reason 5 O O
at Reason 5 O O
both Reason 5 O O
4 Reason 5 O O
and Reason 5 O O
12 Reason 5 O O
weeks Reason 5 O O
with Reason 5 O O
4 Reason 5 O O
(67%) Reason 5 O O
patients Reason 5 O O
achieving Reason 5 O O
a Reason 5 O O
pain Reason 5 O O
reduction Reason 5 O O
of Reason 5 O O
30% Reason 5 O O
at Reason 5 O O
the Reason 5 O O
4-week Reason 5 O O
mark Reason 5 O O
and Reason 5 O O
3 Reason 5 O O
(50%) Reason 5 O O
acheiving Reason 5 O O
the Reason 5 O O
same Reason 5 O O
pain Reason 5 O O
reduction Reason 5 O O
at Reason 5 O O
the Reason 5 O O
12-week Reason 5 O O
mark. Reason 5 O O
No O O O O
significant O O O O
changes O O O O
in O O O O
joint O O O O
inflammation, O O O O
as O O O O
assessed O O O O
by O O O O
the O O O O
40-joint O O O O
sonography, O O O O
was O O O O
observed. O O O O
Regarding O O O O
adverse O O O O
events, O O O O
no O O O O
infection O O O O
was O O O O
reported O O O O
among O O O O
all O O O O
patients O O O O
during O O O O
the O O O O
12-week O O O O
treatment O O O O
period. O O O O
However, O O O O
an O O O O
elevated O O O O
level O O O O
of O O O O
low-density O O O O
lipoprotein O O O O
cholesterol O O O O
in O O O O
1 O O O O
patent O O O O
receiving O O O O
tocilizumab O O O O
at O O O O
week O O O O
12 O O O O
was O O O O
reported. O O O O
There O O O O
were O O O O
possible O O O O
differentially O O O O
expressed O O O O
genes O O O O
identified O O O O
in O O O O
primary O O O O
patients O O O O
when O O O O
compared O O O O
with O O O O
controls O O O O
after O O O O
treatment O O O O
with O O O O
tocilizumab. O O O O
Additionally, O O O O
2 O O O O
genes O O O O
upregulated O O O O
in O O O O
patients O O O O
with O O O O
fibromyalgia O O O O
(C3ARI O O O O
and O O O O
PI3) O O O O
when O O O O
compared O O O O
with O O O O
matched O O O O
health O O O O
controls. O O O O
Investigators O O O O
noted O O O O
several O O O O
limitations, O O O O
including O O O O
the O O O O
small O O O O
sample O O O O
size. O O O O
Additionally, O O O O
the O O O O
observational O O O O
study O O O O
design O O O O
lent O O O O
itself O O O O
to O O O O
potential O O O O
placebo O O O O
effects. O O O O
The O O O O
follow-up O O O O
periods O O O O
within O O O O
the O O O O
fibromyalgia O O O O
cohort O O O O
was O O O O
relatively O O O O
short O O O O
and O O O O
the O O O O
improvement O O O O
in O O O O
symptoms O O O O
may O O O O
not O O O O
be O O O O
clinically O O O O
significant. O O O O
Therefore, O O O O
investigators Reason 2 O O
warned Reason 2 O O
the Reason 2 O O
therapeutic Reason 2 O O
efficacy Reason 2 O O
of Reason 2 O O
tocilizumab Reason 2 O O
is Reason 2 O O
doubtful. Reason 2 O O
Lastly, O O O O
generalizability O O O O
of O O O O
results O O O O
may O O O O
be O O O O
hindered O O O O
as O O O O
all O O O O
patients O O O O
were O O O O
Han O O O O
Chinese. O O O O
Despite O O O O
these O O O O
limitations, O O O O
the O O O O
study O O O O
sheds O O O O
light O O O O
on O O O O
newer O O O O
treatment O O O O
options O O O O
for O O O O
patients O O O O
with O O O O
refractory O O O O
fibromyalgia. O O O O
"Fibromyalgia Reason 5 O O
is Reason 5 O O
a Reason 5 O O
distressful Reason 5 O O
disorder, Reason 5 O O
partly Reason 5 O O
due Reason 5 O O
to Reason 5 O O
the Reason 5 O O
modest Reason 5 O O
therapeutic Reason 5 O O
efficacy Reason 5 O O
of Reason 5 O O
the Reason 5 O O
current Reason 5 O O
treatment," Reason 5 O O
investigators Reason 5 O O
concluded. Reason 5 O O
"Our Reason 5 O O
results Reason 5 O O
unveiled Reason 5 O O
the Reason 5 O O
potential Reason 5 O O
efficacy Reason 5 O O
of Reason 5 O O
subcutaneous Reason 5 O O
tocilizumab Reason 5 O O
on Reason 5 O O
some Reason 5 O O
refractory Reason 5 O O
fibromyalgia Reason 5 O O
patients." Reason 5 O O
References O O O O
